Clinical Trials
62 trialsDESCENT-1
A2 Biotherapeutics Inc.
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
LONGEVITI
University of Alberta
iCaRe2
University of Nebraska
DP-04
AstraZeneca
BASECAMP-1
A2 Biotherapeutics Inc.
CER
Cancer Support Community, Research and Training Institute, Philadelphia
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
National Institutes of Health Clinical Center (CC)
TraveraRTGx
Travera Inc
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
(CLOCS-2)
Imperial College London
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
National Cancer Institute (NCI)
CAMPERR
Adela, Inc
SCORE
Natera, Inc.
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Memorial Sloan Kettering Cancer Center
CCANED-CIPHER
Dysplasia Diagnostics Limited
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
City of Hope Medical Center
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
University of Southern California
LIBERATE
University Health Network, Toronto
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
AstraZeneca
Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes
Memorial Sloan Kettering Cancer Center
OLAP
AstraZeneca
PRIORITY
Institut Bergonié
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Tissue Oximetry's Measurement in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
PREFER
Labcorp Corporation of America Holdings, Inc
INSPIRE
Singlera Genomics Inc.
MOHCCN-O
University Health Network, Toronto
ROOT
Taproot Health
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
QUANTUM
VitaMed Research LLC
AURA
UNC Lineberger Comprehensive Cancer Center
RADIANT
DxTerity Diagnostics
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Beijing Friendship Hospital
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
Namida Lab
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
National Institutes of Health Clinical Center (CC)
CADENCE
MiRXES Pte Ltd
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
Wuhan Ammunition Life-tech Co., Ltd
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Exact Sciences Corporation
WiZen
Technische Universität Dresden
DETECT
Boryung Pharmaceutical Co., Ltd
PASSION
Assistance Publique - Hôpitaux de Paris
SPACE2
Weprom
ADOPT
University of Dundee
Continuation of Follow-up of DES-Exposed Cohorts
National Institutes of Health Clinical Center (CC)
Study to Evaluate the Safety of Nanoxel M Inj.
Samyang Biopharmaceuticals Corporation
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center